Condition
Obesity or Overweight
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 23 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
23 shownA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesNCT07843485 · 2026-09-30
RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular DiseaseNCT07843472 · 2026-09-30
RECRUITINGA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or ObesityNCT07843498 · 2026-09-30
RECRUITINGA Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNCT07776509 · 2026-08-24
RECRUITINGA Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNCT07784270 · 2026-08-20
RECRUITINGA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19
RECRUITINGEfficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 · 2026-05-11
RECRUITINGA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23
RECRUITINGA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16
RECRUITINGStudy on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionNCT07128888 · 2025-11-17
RECRUITINGMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · 2025-06-26
RECRUITINGMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · 2025-06-26
RECRUITINGA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686 · 2026-09-30
NOT_YET_RECRUITINGA Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT07081958 · 2025-07-29
COMPLETEDA Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes MellitusNCT06988553 · 2025-06-17
COMPLETEDA Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18
COMPLETEDStudy of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health ConditionsNCT06867718 · 2025-01-24
COMPLETEDEffects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityNCT06579092 · 2024-10-08
COMPLETEDA Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06595238 · 2024-10-01
COMPLETEDA Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 · 2023-08-15
COMPLETEDA Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 · 2023-04-03
COMPLETEDA Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in SwitzerlandNCT05153590 · 2021-12-03
COMPLETEDObesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican AdultsNCT03629301 · 2018-09-17
COMPLETEDCommon interventions
PlaceboDRUG8PlaceboCOMBINATION_PRODUCT5AZD6234DRUG4EnicepatideCOMBINATION_PRODUCT3PetrelintideCOMBINATION_PRODUCT3Placebo comparatorDRUG3AZD5004DRUG2CagrilintideDRUG2MirikizumabDRUG2Placebo SemaglutideDRUG2SemaglutideDRUG2TirzepatideDRUG2AZD9550DRUG1Enicepatide-matching PlaceboCOMBINATION_PRODUCT1GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tabletsDRUG1ID-DPP groupBEHAVIORAL1LenbelintideDRUG1Maridebart CafraglutideDRUG1PetrelintideDRUG1Petrelintide-matching PlaceboDRUG1Placebo CagrilintideDRUG1RGT001-075DRUG1RO7795081DRUG1Saxenda®DRUG1Wait-list GroupOTHER1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
RECRUITING12
COMPLETED10
NOT_YET_RECRUITING1
Phase mix
PHASE313
PHASE26
PHASE12
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.